Technology | Patient Positioning Radiation Therapy | October 19, 2015

Orfit Announces CE, FDA Clearance for Proton Therapy Immobilization System

HP Pro Solution designed for high-precision immobilization, patient comfort in brain, head and neck treatments

Orfit Industries, HP Pro Solution, proton therapy immobilization system, ASTRO 2015, CE Mark, FDA clearance

Image courtesy of Orfit Industries

October 19, 2015 — Orfit Industries introduced and demonstrated its HP Pro Solution, an innovative, comprehensive and versatile immobilization system for proton therapy, at the American Society for Radiation Oncology (ASTRO) 57th annual meeting. The technology, designed for brain, head and neck treatments, has received U.S. Food and Drug Administration (FDA) 510(k) clearance.

When used with Orfit’s ultra-thin and stable Nanor immobilization masks, based on nanotechnology, HP Pro offers a unique combination of high-precision immobilization and patient comfort.

The British Royal Infirmary in Bristol, United Kingdom, has recently introduced a new gamma knife treatment using the Orfit radiotherapy mask. The treatment has been welcomed by specialists as a non-invasive, potential life-saver, helping to kill off unwanted growths of brain tumors with one millimeter precision, without harming healthy brain tissue.

The HP Pro hardware is designed for use in both proton and photon therapy. The products are homogenous, low density, lightweight and available in a range of configurations including overlays, extensions and a combination overlay/extension in one product. A full range of accessories, including patient-customized head rests, is available.

For more information: www.orfit.com

Related Content

IBA Releases Razor Nano Ionization Chamber
News | Proton Therapy | September 22, 2017
September 22, 2017 — IBA (Ion Beam Applications S.A.) announced the release of the Razor Nano Chamber, the smallest a
Penn Medicine Treats World's First Patient on Varian's Halcyon System
News | Radiation Therapy | September 22, 2017
September 22, 2017 — Varian Medical Systems announced a patient at Penn Medicine, with head & neck cancer, became
BrainLAB Announces FDA Clearance For Two New Indication-Specific Radiosurgery Software Applications
Technology | Treatment Planning | September 21, 2017
Brainlab announced that it has received U.S. Food and Drug Administration (FDA) clearance for Elements Spine SRS and...
Accuray Showcases CyberKnife and Radixact Systems at ASTRO 2017
News | Radiation Therapy | September 21, 2017
Accuray Inc. announced that data and first-hand experience with its advanced CyberKnife and Radixact Systems will be...
RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Overlay Init